NEW YORK ( TheStreet) -- CardioNet (BEAT) was one of several stocks moving on above-average volume Monday as concerns over national healthcare reimbursements for the medical technology company's services drove shares lower.
CardioNet said the Centers for Medicare and Medicaid Services (CMS) proposed that that the technical component of mobile cardiovascular telemetry remains carrier-priced for calendar year 2011. The CMS will give it final rule by Nov. 1 for implementation on Jan. 1, 2011, and if adopted means that local Medicare contractors will decide on reimbursement amounts.
"Given our efforts to obtain a national reimbursement rate for CardioNet's MCOTTM technology, we are disappointed in CMS' Proposed Rule," CardioNet CEO Joe Capper said in a statement. "We will work diligently during the public comments period to request that CMS change its recommendation to one that is more beneficial to Medicare recipients who depend on MCOTTM."
CardioNet shares were down 76 cents, or 10.6%, to $6.42. Volume topped 938,000 shares, compared to the 50-day average daily volume of 406,000, according to the Nasdaq.Elsewhere, Rexahn Pharmaceuticals (RNN) dropped by 17 cents, or 9.9%, to $1.55 after the drug company said it has raised $10 million through a registered direct offering. Institutional investors bought units consisting of one share of common stock and a warrant to purchase 0.3 of a share of common stock at a purchase price of $1.50. Rexahn said net proceeds of approximately $9.45 million will be used for further development of the company's lead clinical programs, including the funding of Rexahn's Phase II clinical study program of serdaxin, zoraxel and archexin. Rexahn's volume topped 832,000 shares, compared to the three-month average daily volume of 2.13 million, according to Yahoo! Finance. -- Written by Robert Holmes in Boston. Follow Robert Holmes on Twitter and become a fan of TheStreet.com on Facebook.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV